ESTRO 2024 - Abstract Book

S1146

Clinical - Haematology

ESTRO 2024

1. Quéro L, Labidi M, Bollet M, Bommier C, Guillerm S, Hennequin C, Thieblemont C. Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma. World J Gastrointest Oncol 2021; 13(10): 1453-1465.

2. Pereira-Da Silva MV, Di Nicola ML, Altomare F, Xu W, Tsang R, Laperriere N, Krema H. Radiation therapy for primary orbital and ocular adnexal lymphoma. Clin Transl Radiat Oncol. 2022 Oct 8;38:15-20.

3. Natsuko Watanabe, Hiroto Narimatsu, Jaeduk Yoshimura Noh, et al, Long-Term Outcomes of 107 Cases of Primary Thyroid Mucosa-Associated Lymphoid Tissue Lymphoma at a Single Medical Institution in Japan. The Journal of Clinical Endocrinology & Metabolism, 2018; 103(2): 732-739.

4. Deantonio L, Pinnix CC, Tsang R. Radiation therapy of extranodal marginal zone lymphomas. Ann Lymphoma 2020;4:16.

1087

Digital Poster

TBI-based conditioning regimen vs chemotherapy prior to transplant in ALL. A study from the SFGM-TC.

Yazid Belkacemi 1 , Kamel Debbi 1 , Nhu Hanh To 1 , Gabriele Coraggio 1 , Mohamed Aziz Cherif 1 , Regis Peffault de La Tour 2 , Laurent Quero 3 , Helene Labussiere-Wallet 4 , Isabelle Martel-Lafay 5 , David Beauvais 6 , Xavier Mirabel 7 , Edouard Fourcade 8 , Stephanie Batard 9 , Raynier Devillier 10 , Laurence Gonzague-Casabianca 11 , Patrice Chevallier 12 , Valentine Guimas 13 , Mohamad Mohty 14 , Johan Maertens 15 , Xavier Poire 16 , Patrice Ceballos 17 , Cristina Castilla-Llorente 18 , Stephanie Nguyen Quoc 14 , Marie Robin 2 , Gokoulakrichenane Loganadane 1 1 APHP-GHU Henri Mondor, Radiation Oncology, Creteil, France. 2 APHP-GHU NORD, Hematology, Paris, France. 3 APHP-GHU NORD, Radiation Oncology, Paris, France. 4 CHU Lyon Sud, Hematology, Lyon, France. 5 Centre Leon Berard, Radiation Oncology, Lyon, France. 6 CHUR Lille, Hematology, Lille, France. 7 Centre Oscar Lambret, Radiation Oncology, Lille, France. 8 CHU Bordeaux, Hematology, Bordeaux, France. 9 Institut Begronie, Radiation Oncology, Bordeaux, France. 10 Institut Paoli Calmettes, Hematology, Marseille, France. 11 Institut Paoli Calmettes, Radiation Oncology, Marseille, France. 12 CHU de Nates, Hematology, Nantes, France. 13 Institut de Cancerologie de l'Ouest, Radiation Oncology, Nantes, France. 14 APHP-Sorbonne Universite, Hematology, Paris, France. 15 Universite Ziekenhuis, Hematology, Leuven, Belgium. 16 Clinique Universitaire Saint-Luc, Hematology, Bruxelles, Belgium. 17 CHU de Montpellier, Hematology, Montpellier, France. 18 Institut Gustave Roussy, Hematology, Villejuif, France

Purpose/Objective:

Total-body irradiation (TBI) combined to high dose chemotherapy (CT) is a major component of ablative and non ablative conditioning regimens prior allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute lymphoblastic leukemia (ALL) and other hematological malignancies. However, TBI may lead to several late toxic effects, including pneumonitis, cataracts, renal complications, endocrinologic disturbances, secondary malignancies, and in children, growth retardation. During a long time, these toxicities have limited its use in some indications particularly in children. Recent randomized data have restored great interest in TBI compared to CT, including for